Safety of Combining Trintillex 10 mg and Wellbutrin 150 mg
Yes, it is generally safe to start Trintillex (vortioxetine) 10 mg daily together with Wellbutrin (bupropion) 150 mg daily, but you must reduce the vortioxetine dose to 5 mg daily when combining these medications due to a significant pharmacokinetic interaction.
Key Drug Interaction
When bupropion (a strong CYP2D6 inhibitor) is co-administered with vortioxetine, it increases vortioxetine exposure substantially:
The FDA-approved prescribing information for Trintillex explicitly states that the maximum recommended dose is 10 mg/day in known CYP2D6 poor metabolizers 2. Since bupropion creates a pharmacologic equivalent of poor metabolizer status by inhibiting CYP2D6, the same dose reduction principle applies 2.
Recommended Dosing Strategy
If starting both medications together:
- Start vortioxetine at 5 mg daily (not 10 mg)
- Start bupropion at 150 mg daily as planned
- Monitor closely for adverse effects, particularly nausea, dizziness, and serotonergic symptoms
If the patient is already on vortioxetine 10 mg:
- Reduce vortioxetine to 5 mg daily before adding bupropion
- Then initiate bupropion 150 mg daily
Safety Monitoring
While the combination is used clinically and was generally well tolerated in studies 1, monitor for:
- Increased vortioxetine side effects (nausea, dizziness, headache) due to elevated drug levels
- Neuropsychiatric symptoms including mood changes, agitation, or suicidal ideation (both drugs carry black box warnings for this) 3, 2
- Seizure risk - bupropion lowers seizure threshold; avoid in patients with seizure disorders, brain metastases, or eating disorders 3, 4
Clinical Context
This combination may be considered when:
- Monotherapy with either agent has been inadequate
- The patient requires augmentation for treatment-resistant depression
- Bupropion is being added to address specific symptoms (e.g., fatigue, cognitive symptoms, sexual dysfunction)
Dose adjustment is required when vortioxetine is co-administered with bupropion 1, 5, 6. The concomitant therapy was generally well tolerated in clinical studies, with most adverse events being mild or moderate in intensity 1.
Contraindications to Avoid
Do not use this combination if the patient: